Eco Animal Health revenues offset by rising costs
Eco Animal Health, which specialises in the development and marketing of medicines for the control of disease in livestock, saw its pre-tax profit for the year creep higher after revenue gains were slightly offset by rising sales costs.
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
You are now subscribed
Your newsletter sign-up was successful
Want to add more newsletters?
Twice daily
MoneyWeek
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
Four times a week
Look After My Bills
Sign up to our free money-saving newsletter, filled with the latest news and expert advice to help you find the best tips and deals for managing your bills. Start saving today!
Eco Animal Health, which specialises in the development and marketing of medicines for the control of disease in livestock, saw its pre-tax profit for the year creep higher after revenue gains were slightly offset by rising sales costs.
Pre-tax profit was £2.32m (2011: £2.29m) on revenues of £28.3m (2011: £27.1m), while the cost of sales increased from £16.4m to £17.5m year-on-year.
A small amount of additional income (£0.76m compared to £0.18m the previous year) helped to boost profits higher.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Diluted earnings per share were 4.19p against 2.96p the previous year, with income pushed higher by the continued growth of the consumption of meat protein and the animal industry.
UK sales grew more than 30% during the year, reflecting the continued success of its direct-to-market strategy with its Aivlosin product.
Peter Lawrence, Executive Chairman of ECO Animal Health Group, said: "ECO has delivered another strong set of results for the year ended March 31st and the current year has started well.
"We are confident that the long awaited marketing authorisations in the US and Canada will have a major positive effect on the development of ECO, although it will be some months before the product launches gain momentum. We do not expect a noticeable impact on our financial performance until next year.
"ECO is very well placed to further broaden its product ranges and its global reach will ensure that it capitalises on opportunities as they arise in all the Company's major markets."
The share price fell 0.39% o 256.50p by 12:10.
NR
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.
-
Average UK house price reaches £300,000 for first time, Halifax saysWhile the average house price has topped £300k, regional disparities still remain, Halifax finds.
-
Barings Emerging Europe trust bounces back from Russia woesBarings Emerging Europe trust has added the Middle East and Africa to its mandate, delivering a strong recovery, says Max King
